Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.raymedlab.com | |
Market Cap | 0.79 Cr. | |
Enterprise Value(EV) | 0.79 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -0.31 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.90 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | -5.17 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | -0.36 | Calculated using Price: 1.86 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 0.43 Cr. | 4,273,500 Shares |
FaceValue | 10 | |
Company Profile | ||
Raymed Labs was established in 1994 as a pharmaceutical company with emphasis on injectables with state of the art manufacturing facilities. the company is located at Dehradun Road, Saharanpur, UP. Manufacturing pharmaceutical products, as such, is a specialized job, however, manufacturing of injectables is even more difficult since they are normally given during a life saving situation thus their quality standards are much more stringent. Raymed's quality quickly won the trusts of doctors and it established itself as one of the leading quality manufacturers of medicines in the area. |
1 Day |
|
|
1 Week |
|
|
1 Month |
|
|
3 Month |
|
+24.83% |
6 Month |
|
+2.76% |
1 Year |
|
+47.62% |
2 Year |
|
+91.75% |
5 Year |
|
-20.17% |
10 Year |
|
-86.32% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | ||||||||||
Return on Capital Employed (%) | -13.45 | -7.11 | -15.55 | -26.39 | -41.34 | -58.42 | -105.49 | -94.35 | ||
Return on Assets (%) | -12.03 | -6.08 | -12.90 | -17.98 | -20.71 | -20.01 | -21.34 | -27.07 | -32.96 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | |
Non Curr. Liab. | 2 | 2 | |||||||||
Curr. Liab. | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | |
Minority Int. | |||||||||||
Equity & Liab. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Non Curr. Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Curr. Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | |||||||||||
Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Total Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Total Expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
PBIDT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Interest | |||||||||||
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
Taxation | |||||||||||
Exceptional Items | 0 | 0 | 0 | 0 | 0 | ||||||
PAT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | 0 | 0 | -2 | ||||||
Cash Fr. Inv. | 0 | 2 | |||||||||
Cash Fr. Finan. | 0 | 0 | 0 | ||||||||
Net Change | 0 | 0 | |||||||||
Cash & Cash Eqvt | 0 |
Tue, 24 Jan 2023
Board Meeting Intimation for Approval Of Unaudited Financial Results RAYMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2023 inter alia to consider and approve Unaudited Financial Results for the quarter ended December 31 2022 |
Thu, 12 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Reg 74(5) of SEBI (DP) Reg 2018 for the quarter ended 31st December 2022 |
Tue, 27 Dec 2022
Closure of Trading Window Intimation for Closure of Trading Window for Quarter ended December 31 2022 |
Mon, 23 Jan 2023 |
|
|
|
|
|